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abstract: Non-invasive gamete and embryo assessment is considered an important focus in assisted reproductive technologies (ART).
Currently, the selection of embryos for transfer is based on morphological indices. Though successful, the ﬁeld of ART would beneﬁt from a
non-invasive quantitative method of viability determination. Omics technologies, including transcriptomics, proteomics and metabolomics,
have already begun providing evidence that viable gametes and embryos possess unique molecular proﬁles with potential biomarkers that
can be utilized for developmental and/or viability selection. Unlike the human genome that is relatively ﬁxed and steady throughout the
human body, the human proteome, estimated at over a million proteins, is more complex, diverse and dynamic. It is the proteins themselves
that contribute to the physiological homeostasis in any cell or tissue. Of particular interest in ART is the secretome, those proteins that are
produced within the embryo and secreted into the surrounding environment. Deﬁning the human embryonic secretome has the potential to
expand our knowledge of embryonic cellular processes, including the complex dialogue between the developing embryo and its maternal
environment, and may also assist in identifying those embryos with the highest implantation potential. Advances in proteomic technologies
have allowed the non-invasive proﬁling of the human embryonic secretome with ongoing research focused on correlation with outcome.
From a clinical perspective, embryo selection based on morphological assessment and non-invasive analysis of the human embryonic secre-
tome may improve IVF success and lead to routine single embryo transfers.
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Introduction
Over the last decade, there has been a strong focus on the molecular
characterization of various biological systems and disease states. The
human genome consists of 25 000 genes with the human transcrip-
tome providing researchers with valuable gene expression data.
However, it is the human proteome deﬁned as the PROTEin comp-
lement to the human genOME that actually dictates cellular function
and ultimately determines phenotype (Fig. 1). The proteome itself is
dynamic, constantly changing through its own interactions, impacted
by both internal and external stimuli. Advances in proteomic technol-
ogies have begun to shed light on the diversity and complexity of the
human proteome, estimated at over 1 million proteins. A variety of
biological samples are under investigation, with an emphasis towards
identifying proteins involved in speciﬁc disease states, to develop
new diagnostic and prognostic assays (Dominguez et al., 2007). Of
particular interest to investigators is the secretome, those proteins
that are produced by cells and secreted at any given time or under
certain physiological conditions (Hathout, 2007). Several types of bio-
logical ﬂuids, including serum and conditioned medium, have been ana-
lyzed for secreted proteins that may deﬁne a particular disease state
or progression (Hu et al., 2006; Kulasingam and Diamandis, 2007).
A number of putative cancer biomarkers have been discovered from
analysis of serum proteomes from a variety of cancer patients.
Although very promising, some of the candidate biomarkers are rela-
tively abundant, shared among different human cancers and overex-
pressed in other human diseases such as autoimmune diseases (Hu
et al., 2006). Future validation of candidate cancer biomarkers on
large independent patient cohorts is critical. With the development
of new sensitive proteomic technologies, investigators are concentrat-
ing on discovering low abundant serum proteins that are more sensi-
tive and cancer speciﬁc. In this review, we discuss the role of
proteomics in examining the mammalian embryonic secretome. Deﬁn-
ing and characterizing the mammalian embryonic secretome will
& The Author 2009. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
For Permissions, please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for
non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication
with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For
commercial re-use, please contact journals.permissions@oxfordjournals.org
Molecular Human Reproduction, Vol.15, No.5 pp. 271–277, 2009
Advanced Access publication on February 17, 2009 doi:10.1093/molehr/gap012expand our knowledge of early embryogenesis, advance our under-
standing of the embryonic role during implantation and potentially
contribute to the development of non-invasive viability assessment.
Embryo assessment
Theselectionofembryosfortransferiscurrentlybasedondetailedmor-
phological criteria (Ebner et al., 2003). Though relatively successful, the
ﬁeld of assisted reproductive technologies (ART) would beneﬁt from
more quantitative methods of viability determination to improve IVF
success and reduce the incidence of multiple pregnancies (Sakkas and
Gardner, 2005). Over the last decade, a decrease in the number of
embryos for transfer has correlated with a signiﬁcant reduction in
higher order pregnancies (Stern et al., 2007). However, twin gestations
continuetoreﬂectahighpercentageofIVFpregnancieswithhighhealth
risks to both the mother and fetuses, including preterm delivery, low
birthweight, perinatal mortality and other pregnancy-related compli-
cations(Pinborg,2005).Hence,thepromiseofimprovingIVFpregnancy
rateswithmorequantitativemethodsofembryoselectionhastheability
to optimize successful single embryo transfer.
Proteomics and the mammalian
embryo
Proteins translated from RNA transcripts are directly responsible for
cellular function as illustrated in Fig. 1. Gene expression studies of
these RNA transcripts, though valuable, have been shown to often
not predict protein abundance or function. For example, low levels
of correlation were observed in a study where paired comparisons
of changes in mRNA and protein expression levels were investigated
in embryonic stem cells (Williamson et al., 2008). Furthermore,
while examining the relationship between proteins and mRNA abun-
dance in yeast, mRNA transcript analyses were found to be insufﬁcient
in predicting protein expression (Gygi et al., 1999). Several mechan-
isms, including targeted mRNA degradation and protein degradation,
can be utilized by the cell during regulation of transcription/translation
resulting in a lack of association between gene expression, RNA tran-
scripts and protein expression. Consequently, in order to understand
cellular function and comprehend biological processes and/or disease
states, an in depth investigation of the mammalian proteome is vital.
Despite new advances in proteomic technologies, knowledge of the
proteome of the mammalian preimplantation embryo remains limited.
The combined effect of limited template, low protein expression and
the lack of sensitivity of proteomics platforms have contributed as the
main hurdles. In spite of these obstacles, therehave been several excel-
lent publications, a selection of these are described in Table I. Earlier
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Table I Selected publications highlighting the use of proteomics in embryo assessment/development
Model Characterization Key ﬁndings Reference
Mouse 2D gel electrophoresis Constructed a 2D gel protein database for the mouse embryo. Characterized changes in
protein synthesis patterns during normal preimplantation development from fertilization to
blastocyst stage
Latham et al. (1992)
Mouse 2D gel electrophoresis Constructed protein databases for compacted 8-cell and blastocyst stage mouse embryos.
Documented the overall quantitative changes in protein levels
Shi et al. (1994)
Rabbit Western blot Insulin-responsive glucose transporter protein isoforms (GLUT4 and GLUT8) and the insulin
receptor protein were expressed in rabbit blastocysts
Navarrete Santos
et al. (2004)
Mouse Western blot An increase in phosphorylation of SAPK/JNK and p38MAPK negatively correlate with mouse
embryo development
Wang et al. (2005)
Porcine MALDI-TOF MS western
blot
Major vault protein (MVP) accumulated in embryos that failed to develop normally in vitro Sutovsky et al. (2005)
Mouse SELDI-TOF MS Embryos generated under 5% (low) oxygen more closely resembled in vivo-derived mouse
embryos. High (20%) oxygen conditions were associated with down-regulation of 10 proteins/
biomarkers
Katz-Jaffe et al. (2005)
Human SELDI-TOF MS Different protein proﬁles were identiﬁed between early and expanded blastocysts, and
between developing blastocysts and degenerating embryos
Katz-Jaffe et al.
(2006a)
SAPK/JNK, stress-activated protein kinase/Jun kinase; p38 MAPK, 38 mitogen-activated protein kinase; MALDI-TOF MS, matrix-assisted laser desorption ionization–time-of-ﬂight mass
spectrometry; SELDI-TOF MS, surface-enhanced laser desorption/ionization–time of ﬂight mass spectrometry.
Figure 1 A schematic diagram outlining the complexity of cellular
function including associated omics technologies; genomics, transcrip-
tomics, proteomics and metabolomics that contribute to the study
and understanding of biological systems.
272 Katz-Jaffe et al.proteomic studies utilized two-dimensional (2D) gel electrophoresis in
combination with computerized analysis of gel images to construct
and analyze protein databases of the preimplantation mouse embryo
(Latham et al., 1992; Shi et al., 1994). Western blotting has also been
used to identify the expression of known proteins (Navarrete Santos
et al., 2004), or to detect post-translational modiﬁcations, like phos-
phorylation, in relation to embryo development (Wang et al., 2005).
More recently, advances in proteomic technologies, with the develop-
ment of mass spectrometry (MS), have made it possible to identify
groups of proteins within limited amounts of complex biological ﬂuids
and tissues (Gutstein et al., 2008; Jansen et al., 2008).
MS: a powerful tool in global
proteomics
MS has rapidly become an important technology in proteomic proﬁling.
Searching for consistent and signiﬁcant alteration in protein expression
proﬁlingbetweenspeciﬁcgroupsofsampleshaverevealedimportantfea-
turesofadiseasestateorphysiologicalprocess.MSinvolvesanionsource
for production of a charged species in the gas phase, and an analyzer,
which can separate ions by their mass-to-charge (m/z) ratio. Several
commonly used ionization methods include electrospray ionization and
surface-enhanced laser desoprtion/ionization (SELDI), which are
coupledtotime-of-ﬂight(TOF),iontraporquadrupoleanalyzers.SELDI-
TOF MS, with speciﬁc capture afﬁnity protein chips, has allowed fast,
cost-effective, high-throughput analysis of small sample volumes (micro-
liter range) and enables sensitivity to be in the picomole to femtomole
range. Bound proteins are laser activated thereby liberating gaseous




of biological tissues and ﬂuids with speciﬁc focus on oncoproteomics
including the early detection, metastases ability and therapeutic
outcomeofanassortmentofdifferentcancers(Cho,2007).Identiﬁcation
ofproteinsfollowingMSproﬁlingistypicallyperformedbyproteasediges-
tion generating distinct cleavage products identiﬁable by tandem MS
analysis and protein database searching (Liebler, 2002).
MS technology has begun to be utilized as a proteomic platform in
the study of the developing preimplantation embryo (Table I). The
major vault protein (MVP) was identiﬁed using matrix-assisted laser
desorption ionization–time-of-ﬂight (MALDI-TOF) MS and western
blotting as a protein expressed in porcine preimplantaion embryos.
MVP was shown to accumulate in poor-quality porcine embryos
that failed to develop normally in vitro (Sutovsky et al., 2005). In
addition, SELDI-TOF MS has recently been used to generate protein
proﬁles at all stages of mammalian embryonic development (Katz-Jaffe
et al., 2005, 2006a). Differences in protein proﬁles were observed
between early and expanded blastocysts as well as between develop-
ing blastocysts and degenerate embryos. Preliminary database search-
ing identiﬁed some of the protein candidates to be directly linked to
embryogenesis (Katz-Jaffe et al., 2006a).
The dynamic and sensitive nature of the proteome to variables
during sample collection, storage, handling and processing needs to
be considered and a consistent protocol needs to be followed for
reproducible proteomic data (Hu et al., 2005). Data prejudice
caused by MS calibration and instrument drift overtime and across
labs can also introduce artifacts. This can be controlled for by
running samples in replicates, routinely performing internal and exter-
nal calibrations and including suitable control samples with every run.
The embryonic secretome
It is proposed that viable embryos possess a unique proteome with
potentially some of these proteins secreted into the surrounding
culture medium contributing to the secretome. Consequently, a non-
invasive proteomic analysis of the secretome of mammalian embryos
throughout preimplantation development may assist in revealing
secreted factors that reﬂect developmental competence and viability.
One of the earliest studies of the human embryonic secretome
revealed the release of 1-o-alkyl-2-acetyl-sn-glycero-3-phosphocholine
(paf), a soluble factor that is produced and secreted by mammalian
preimplantation embryos. paf operates in an autocrine manner as a
survival factor during embryonic development. It also creates a
range of alterations to maternal physiology including platelet activation
(O’Neill, 2005). Leptin, a small pleiotrophic peptide, has also been
observed in the conditioned medium from blastocysts in a human
in vitro model studying the interactions between the embryo and endo-
metrial epithelial cells (Gonzalez et al., 2000). It was shown that com-
petent human blastocysts secreted higher leptin concentrations into
the surrounding medium than arrested embryos. It has been hypoth-
esized that the leptin secreted by the blastocyst initiates a ligand
receptor-mediated effect with leptin receptors in the maternal endo-
metrium establishing a molecular dialogue during the window of
implantation (Cervero et al., 2005).
Acrogranin, a protein that regulates epithelial cell growth, has been
shown to be secreted into the surrounding media by preimplantation
mouse embryos (Dı ´az-Cueto et al., 2000). Upon addition of acrogra-
nin to culture medium, blastocyst formation was promoted. Acrogra-
nin is believed to act directly on the trophectoderm cells in an
autocrine manner. Furthermore, this study revealed that addition of
anti-acrogranin antibodies to the surrounding media delayed the
onset of blastocyst formation. It has been suggested that acrogranin
is expressed by the uterus and inﬂuences embryo development
similar to that of exogenous added acrogranin that promotes blasto-
cyst formation in culture (Dı ´az-Cueto et al., 2000).
More recently, Sakkas et al. (2003) characterized a soluble molecule
secreted by human blastocysts that modulates regulation of HOXA10
expression in an epithelial endometrial cell line. This form of reciprocal
embryo-endometrial interaction could transform the local uterine
environmentimpactingbothembryodevelopmentandtheimplantation
process.Inaddition,thedetectionofsolublehumanleukocyteantigenG
(sHLA-G) in spent IVF medium of Day 3 embryos has indicated higher
pregnancy rates from sHLA-G-positive embryos (Noci et al., 2005;
Sher et al., 2005). These results however have not been absolute with
pregnancies established from sHLA-G-negative embryos. Additionally,
technical differences have been recorded including the inability to
measure sHLA-G production in some supernatants (Sargent et al.,
2007). Overall, each of these individual secretome studies has focused
ononlythesinglevariable.Consideringthemultifactorialnatureofmam-
malian embryonic development, it would be reasonable to assume that
morethanonesinglefactorwouldberequiredtopredictdevelopmental
competence and/or implantation potential.
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Using SELDI-TOF MS, distinctive secretome signatures were observed
at each 24 h embryonic developmental stage from the time of fertiliza-
tion to the blastocyst stage. These secretome signatures could
uniquely identify the embryonic stages of development, independent
of morphology. Some proteins were observed across several embryo-
nic stages, whereas others were more stage-speciﬁc (Katz-Jaffe et al.,
2006b). Interestingly, species comparison between the mouse and
human embryonic secretome revealed limited diversity; similar to
the protein paf which has been observed in the secretome of all mam-
malian species studied to date (O’Neill, 2005).
Thetransitionfrommaternalinheritedtranscriptsandproteinstothe
activationof the embryonic genome and the expressionof keyembryo-
nicproteinsmustoccurforcontinuedembryonicdevelopment (Telford
et al., 1990). In particular, unique proteins were observed in the human
embryonic secretome after the activation of the embryonic genome
(Katz-Jaffe et al., 2006b). Thus, embryos with a correctly activated
embryonic genome, and hence, a fully functional embryonic proteome
and secretome may have a higher potential of developmental compe-
tence. Correlation of secretome signatures with ongoing blastocyst
development revealed an 8.5 kDa protein. The limited expression of
this 8.5 kDa protein from the secretome of degenerating embryos, in
conjunction with its signiﬁcantly high expression from the secretome
of developing blastocysts, potentially indicates an association between
this protein and developmental competence (P , 0.05). Tandem MS
and database peptide sequence identiﬁcation indicated that the best
candidate for this 8.5 kDa protein was ubiquitin (Katz-Jaffe et al.,
2006b). Ubiquitin is a component of the ubiquitin-dependent proteo-
some system, targeting proteins for degradation. The system is involved
in a number of physiological processes including proliferation and apop-
tosis. Secreted ubiquitin has been shown to be up-regulated in body
ﬂuids in certain disease states and this accumulation provides evidence
for an increased protein turnover (Sandoval et al., 2006; Delbosc
et al., 2008). Ubiquitin has also been implicated to play a crucial role
duringmammalianimplantationbycontrollingtheactivitiesandturnover
of key signaling molecules (Wang et al., 2004). Ongoing research is
focused on identiﬁcation of the remaining secreted proteins as well as
correlation with both developmental competence and implantation.
Another aspect of ART that could beneﬁt from non-invasive analysis
is preimplantation genetic screening (PGS). PGS involves the biopsy of
polar bodies or embryonic cells and has become a routine clinical pro-
cedure in many IVF clinics screening for speciﬁc chromosomal
abnormalities in human embryos. Biopsy procedures are invasive to
the growing embryo and could potentially compromise further devel-
opment. An initial investigation into whether embryos with chromoso-
mal abnormalities could be distinguished from euploid embryos by
their respective secretome identiﬁed hatching blastocysts euploid for
10 chromosomes to exhibit notably different secretome proﬁles to
hatching blastocysts identiﬁed as aneuploid for 10 chromosomes. In
addition, degenerating aneuploid embryos exhibited a signiﬁcantly
different secretome proﬁle to hatching aneuploid blastocysts (Katz-
Jaffe et al., 2006c).
With further advances in genomics technologies allowing for com-
prehensive chromosomal analysis of all 23 pairs of chromosomes on
a single cell (Fragouli et al., 2008), an integrated ‘omics’ approach
has become realistic, discriminating secretome signatures between
individual euploid and aneuploid blastocysts. Microdrops of spent
IVF culture medium from individual blastocysts of transferable quality
were processed (n ¼ 33) and analyzed by SELDI-TOF MS determining
a blastocyst secretome ﬁngerprint. Each individual blastocyst was then
subjected to comparative genomic hybridization for comprehensive
chromosomal analysis of all 23 pairs of chromosomes; with n ¼ 19
identiﬁed as euploid and n ¼ 14 as aneuploid (Fragouli et al., 2008).
Of the 14 aneuploid blastocysts, 9 had a single chromosomal aneu-
ploidy and 5 were chaotic with more than two chromosomes
involved. Secretome ﬁngerprints from individual blastocysts identiﬁed
protein signatures that allowed discrimination between euploid and
aneuploid chromosomal constitutions (Katz-Jaffe et al., 2008). Follow-
ing statistical analysis, a novel set of nine differentially expressed bio-
markers was identiﬁed (P , 0.05). Each of the nine biomarkers was
reproducible in all 33 secretome samples classifying a euploid secre-
tome/blastocyst from an aneuploid secretome/blastocyst (Katz-Jaffe
et al., 2008). Figure 2 displays box plots of three examples from this
set, including a biomarker that displayed a decrease in expression in
the secretome of aneuploid blastocysts (P , 0.05) (Fig. 2A), and
two biomarkers that were shown to have increased expression in
the secretome of aneuploid blastocysts (P , 0.05) (Fig. 2B and C).
Ongoing research is focused on increasing the sample size to
conﬁrm reproducibility including a prospective analysis to validate
the discrimination of euploid and aneuploid blastocysts. The ability
to non-invasively assay for the combination of developmental compe-
tence and chromosomal constitution could represent a powerful via-
bility selection tool in ART.
Protein microarray
In addition to MS technology, there are other proteomics platforms
under investigation that show promise for deﬁning the human embryo-
nic secretome. In particular, protein microarrays have the added
advantage of offering complimentary information to gene transcrip-
tome studies as well as eliminating the need for follow-up protein
identiﬁcation. Recently, a study using protein microarrays compared
pooled blastocyst conditioned media with control medium revealing
the increased expression of the soluble tumor necrosis factor (TNF)
receptor 1 and interleukin (IL)-10, and the decreased expression of
macrophage-stimulating protein (MSP)-a, stem cell factor (SCF), che-
mokine (C-X-C motif) ligand 13 (CXCL13), TNF-related apoptosis
inducing ligand receptor 3 (TRAILR3) and macrophage inﬂammatory
protein (MIP)-1b (Dominguez et al., 2008). Further analysis investi-
gating potential differences between pooled conditioned media from
blastocysts that implanted versus pooled media that resulted in
failed implantation revealed the presence of two signiﬁcantly
decreased proteins, CXCL13 and GM-CSF, in the pooled implanted
blastocyst media. GM-CSF is a protein that has previously been ident-
iﬁed in both human and mice blastocyst spent media culture to
promote embryo development and implantation (Robertson, 2007).
The decrease in GM-CSF protein expression, observed by Dominguez
et al. (2008), may indicate an autocrine mechanism in supporting
blastocyst development and potential implantation. None of the
120 proteins included in this protein microarray was observed to be
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blastocysts (Dominguez et al., 2008). Larger sample volume require-
ments and other platform sensitivity limitations restricted the study
to investigate pooled samples in contrast to individual media
samples. Other platform concerns include the high cost of protein
microarrays, the lower number of targets in comparison to MS or
other technologies, and the dependence on the existence of anti-
bodies and potential non-speciﬁc interactions (Spisak et al., 2007).
Metabolites in the human
embryonic secretome
Metabolites, the functional end products of biological processes, are
also under investigation in the secretome using spectroscopy-based
methods coupled with targeted bioinformatics (Brison et al., 2007).
These low molecular weight metabolites have been shown to radi-
cally change to reﬂect a particular metabolic and environmental
state. Raman and Near Infrared Spectroscopy are two methods
that have been used to detect speciﬁc oxidative stress biomarkers
in spent culture medium with highlighted differences in algorithms
generated for positive versus negative IVF outcomes. Viability
indices generated from spent culture media analysis were observed
to be higher for human embryos that went on to produce pregnan-
cies and live births, compared with those that failed to implant (Seli
et al., 2007). In addition, a blinded pilot study on retrospectively col-
lected data, using the Raman spectroscopy platform, revealed an
overall diagnostic accuracy for predicting embryonic reproductive
potential, either delivery or a failed implantation, at 80.5% (Scott
et al., 2008).
Figure 2 Examples of biomarkers that were differentially expressed in the secretome signatures of euploid blastocysts (n ¼ 19) compared with the
secretome signature of aneuploid blastocysts (n ¼ 14) (P , 0.05).
(A) Box plot revealing signiﬁcant decrease in the expression of a 3.1 kDa biomarker in the secretome of aneuploid blastocysts compared with the secretome of euploid
blastocysts (P , 0.0001) (B and C) Two box plots exhibiting signiﬁcant increase in expression of 2.9 and 5.2 kDa biomarkers in the secretome of aneuploid blastocysts
compared with the secretome of euploid blastocysts (P , 0.002 and P , 0.0009, respectively). The upper hinge of the box plot indicates the 75th percentile set, and the
lower hinge the 25th percentile of the data. The internal line represents the median.
Deﬁning the embryonic secretome 275Proteomics and metabolomics are two complementary omics plat-
forms in the investigation of the human embryonic secretome that
show promise for the development of non-invasive methods for
embryo selection in the ﬁeld of ART. With the ability to assay both
proteins and metabolites in spent culture media, generating compli-
mentary but different molecular proﬁles, it is feasible to propose
that embryo viability assessment may include a combination of both
omics platforms.
Discussion
Developments in the ﬁeld of proteomics, in particular improvements
in MS instrument detection, have allowed the analysis of limited
complex biological ﬂuids, including spent culture media, and have facili-
tated fast, sensitive and high-throughput secretome analysis. Ongoing
secretome research using a variety of proteomic platforms will con-
tinue to provide valuable data increasing our understanding of the bio-
logical processes involved in mammalian embryonic development
(Table II). This knowledge may contribute to the evolution of non-
invasive embryo viability assessment for use in ART. Alongside mor-
phology, a non-invasive quantitative method for embryo selection
may optimize successful single embryo transfers, reduce early preg-
nancy losses and increase live births. Deﬁning the embryonic secre-
tome will also provide researchers with insight into the unique
sequences of events that are fundamental for successful implantation,
including the most critical requirements of the blastocyst. Taking into
account the complexity and diversity of the human embryo, it would
seem reasonable to envisage a combined ‘omics’ contribution to the
characterization of the human embryonic secretome.
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